ABVC
Abvc Biopharma, Inc.
$1.80
+0.03 (+1.69%)
At close · Jul 2
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.”View the 10-Q filed May 18, 2026
Market Cap
$46.80M
Shares
26,000,442
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.80
Open$1.78
Day$1.69–1.84
52W$0.88–5.48
Avg vol 30d150K
Short int391K · 1.5% float · 3.5d
Short vol16%
Last earningsMar 3, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 18
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Neutral
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−7% below
+
Price vs 50-day avg
+45% above
−
RSI (14)
77 · overbought
+
MACD trend
positive
◦
52-week position
20% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $1 › 200d $2 — 200d above 50d
−
Institutional flow
-7% holders QoQ · +6 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
1.50% of float · ▲ +51.1% MoM · 3.5 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
14 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+234% Y/Y
+
Gross margin
100%, expanding
◦
EPS growth
+7% Y/Y
−
Free cash flow
$-3.0M
+
Balance sheet
net cash $681.5K
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 18, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−7% below
Bearish
Price vs 50-day avg
+45% above
Bullish
RSI (14)
77 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
20% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.50% of float · ▲ +51.1% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 20%
52-wk high $5
vs 200-day avg -7%
vs 50-day avg +45%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABVC
this stock
Abvc Biopharma, Inc.
|
$46.80M | -15.5% | +234.3% | — | 1.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABVC | +24.1% | +40.6% | -20.0% | +13.9% | -15.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +22.7% | +41.9% | -28.0% | +14.2% | -24.7% |
Key facts
CIK
1173313
CUSIP
00091F304